EW Quote, Financials, Valuation and Earnings

NeuroOne Medical Technologies has a net margin of 27.83% compared to Edwards Lifesciences's net margin of 54.53%. Edwards Lifesciences's return on equity of 50.81% beat NeuroOne Medical Technologies's return on equity of -238.93%.

Edwards Lifesciences has a consensus price target of $80.14, signalling upside risk potential of 9.81%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of -- which suggests that it could grow by 132.56%. Given that NeuroOne Medical Technologies has higher upside potential than Edwards Lifesciences, analysts believe NeuroOne Medical Technologies is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.149, which suggesting that the stock is 14.863% more volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.823%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.

Edwards Lifesciences quarterly revenues are $1.4B, which are larger than NeuroOne Medical Technologies quarterly revenues of $3.3M. Edwards Lifesciences's net income of $385.6M is higher than NeuroOne Medical Technologies's net income of $1.8M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.47x while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 7.64x versus 4.26x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of 27.83% compared to Edwards Lifesciences's net margin of -211%. Edwards Lifesciences's return on equity of 50.81% beat Nutriband's return on equity of -69.58%.

Edwards Lifesciences has a consensus price target of $80.14, signalling upside risk potential of 9.81%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 136.36%. Given that Nutriband has higher upside potential than Edwards Lifesciences, analysts believe Nutriband is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.149, which suggesting that the stock is 14.863% more volatile than S&P 500. In comparison Nutriband has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.944%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

Edwards Lifesciences quarterly revenues are $1.4B, which are larger than Nutriband quarterly revenues of $645.8K. Edwards Lifesciences's net income of $385.6M is higher than Nutriband's net income of -$1.4M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.47x while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 7.64x versus 26.96x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

SINTX Technologies has a net margin of 27.83% compared to Edwards Lifesciences's net margin of -882.81%. Edwards Lifesciences's return on equity of 50.81% beat SINTX Technologies's return on equity of -148.9%.

Edwards Lifesciences has a consensus price target of $80.14, signalling upside risk potential of 9.81%. On the other hand SINTX Technologies has an analysts' consensus of $300.00 which suggests that it could grow by 2700%. Given that SINTX Technologies has higher upside potential than Edwards Lifesciences, analysts believe SINTX Technologies is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.149, which suggesting that the stock is 14.863% more volatile than S&P 500. In comparison SINTX Technologies has a beta of 1.124, suggesting its more volatile than the S&P 500 by 12.355%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.

Edwards Lifesciences quarterly revenues are $1.4B, which are larger than SINTX Technologies quarterly revenues of $192K. Edwards Lifesciences's net income of $385.6M is higher than SINTX Technologies's net income of -$1.7M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.47x while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 7.64x versus 1.56x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Steris PLC has a net margin of 27.83% compared to Edwards Lifesciences's net margin of 12.66%. Edwards Lifesciences's return on equity of 50.81% beat Steris PLC's return on equity of 7.27%.

Edwards Lifesciences has a consensus price target of $80.14, signalling upside risk potential of 9.81%. On the other hand Steris PLC has an analysts' consensus of $250.13 which suggests that it could grow by 12.97%. Given that Steris PLC has higher upside potential than Edwards Lifesciences, analysts believe Steris PLC is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.149, which suggesting that the stock is 14.863% more volatile than S&P 500. In comparison Steris PLC has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.657%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Steris PLC offers a yield of 1.01% to investors and pays a quarterly dividend of $0.57 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Steris PLC pays out 53.03% of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Edwards Lifesciences quarterly revenues are $1.4B, which are larger than Steris PLC quarterly revenues of $1.4B. Edwards Lifesciences's net income of $385.6M is higher than Steris PLC's net income of $173.5M. Notably, Edwards Lifesciences's price-to-earnings ratio is 10.47x while Steris PLC's PE ratio is 47.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 7.64x versus 4.07x for Steris PLC. Usually stocks with elevated PS ratios are considered overvalued.